Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
ALC vs IDXX vs HSIC vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Distribution
Medical - Instruments & Supplies
ALC vs IDXX vs HSIC vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Diagnostics & Research | Medical - Distribution | Medical - Instruments & Supplies |
| Market Cap | $31.13B | $45.45B | $8.09B | $16.97B |
| Revenue (TTM) | $10.58B | $4.45B | $13.18B | $4.13B |
| Net Income (TTM) | $815M | $1.10B | $398M | $544M |
| Gross Margin | 54.9% | 62.1% | 29.1% | 52.8% |
| Operating Margin | 12.3% | 31.6% | 5.8% | 17.5% |
| Forward P/E | 18.1x | 38.3x | 13.2x | 17.2x |
| Total Debt | $5.25B | $1.08B | $3.69B | $2.63B |
| Cash & Equiv. | $1.53B | $180M | $156M | $1.96B |
ALC vs IDXX vs HSIC vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Alcon Inc. (ALC) | 100 | 98.5 | -1.5% |
| IDEXX Laboratories,… (IDXX) | 100 | 181.3 | +81.3% |
| Henry Schein, Inc. (HSIC) | 100 | 116.6 | +16.6% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALC vs IDXX vs HSIC vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ALC is the clearest fit if your priority is income & stability.
- Dividend streak 5 yrs, beta 0.80, yield 0.5%
- 0.5% yield; 5-year raise streak; the other 3 pay no meaningful dividend
IDXX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 10.4%, EPS growth 22.6%, 3Y rev CAGR 8.5%
- 5.6% 10Y total return vs HOLX's 124.3%
- PEG 2.68 vs HSIC's 4.20
- 10.4% revenue growth vs HOLX's 1.7%
HSIC is the clearest fit if your priority is value.
- Lower P/E (13.2x vs 17.2x)
HOLX is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
- Beta 0.41 vs IDXX's 1.35, lower leverage
- +37.1% vs ALC's -32.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.4% revenue growth vs HOLX's 1.7% | |
| Value | Lower P/E (13.2x vs 17.2x) | |
| Quality / Margins | 24.6% margin vs HSIC's 3.0% | |
| Stability / Safety | Beta 0.41 vs IDXX's 1.35, lower leverage | |
| Dividends | 0.5% yield; 5-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +37.1% vs ALC's -32.6% | |
| Efficiency (ROA) | 32.6% ROA vs ALC's 2.6%, ROIC 42.5% vs 4.0% |
ALC vs IDXX vs HSIC vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ALC vs IDXX vs HSIC vs HOLX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IDXX leads in 2 of 6 categories
HSIC leads 1 • HOLX leads 1 • ALC leads 1 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
IDXX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HSIC is the larger business by revenue, generating $13.2B annually — 3.2x HOLX's $4.1B. IDXX is the more profitable business, keeping 24.6% of every revenue dollar as net income compared to HSIC's 3.0%. On growth, IDXX holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $10.6B | $4.4B | $13.2B | $4.1B |
| EBITDAEarnings before interest/tax | $2.2B | $1.5B | $1.1B | $974M |
| Net IncomeAfter-tax profit | $815M | $1.1B | $398M | $544M |
| Free Cash FlowCash after capex | $1.7B | $845M | $561M | $1000M |
| Gross MarginGross profit ÷ Revenue | +54.9% | +62.1% | +29.1% | +52.8% |
| Operating MarginEBIT ÷ Revenue | +12.3% | +31.6% | +5.8% | +17.5% |
| Net MarginNet income ÷ Revenue | +7.7% | +24.6% | +3.0% | +13.2% |
| FCF MarginFCF ÷ Revenue | +16.1% | +19.0% | +4.3% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.3% | +14.3% | +7.7% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -45.7% | +16.6% | +14.9% | -9.2% |
Valuation Metrics
HSIC leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 51% valuation discount to IDXX's 43.7x P/E. Adjusting for growth (PEG ratio), IDXX offers better value at 3.06x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $31.1B | $45.4B | $8.1B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $34.9B | $46.3B | $11.6B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | 32.26x | 43.75x | 21.56x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.14x | 38.29x | 13.25x | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.06x | 6.84x | — |
| EV / EBITDAEnterprise value multiple | 13.66x | 31.60x | 10.87x | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 2.99x | 10.56x | 0.61x | 4.14x |
| Price / BookPrice ÷ Book value/share | 1.44x | 28.75x | 1.79x | 3.43x |
| Price / FCFMarket cap ÷ FCF | 18.02x | 43.14x | 14.12x | 18.44x |
Profitability & Efficiency
IDXX leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
IDXX delivers a 70.9% return on equity — every $100 of shareholder capital generates $71 in annual profit, vs $4 for ALC. ALC carries lower financial leverage with a 0.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to HSIC's 0.77x. On the Piotroski fundamental quality scale (0–9), IDXX scores 7/9 vs HSIC's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.7% | +70.9% | +8.2% | +11.0% |
| ROA (TTM)Return on assets | +2.6% | +32.6% | +3.6% | +6.1% |
| ROICReturn on invested capital | +4.0% | +42.5% | +7.1% | +9.4% |
| ROCEReturn on capital employed | +4.8% | +61.4% | +9.8% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.24x | 0.67x | 0.77x | 0.52x |
| Net DebtTotal debt minus cash | $3.7B | $897M | $3.5B | $667M |
| Cash & Equiv.Liquid assets | $1.5B | $180M | $156M | $2.0B |
| Total DebtShort + long-term debt | $5.2B | $1.1B | $3.7B | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | 8.23x | 35.55x | 4.59x | 8.00x |
Total Returns (Dividends Reinvested)
Evenly matched — IDXX and HOLX each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HOLX five years ago would be worth $11,582 today (with dividends reinvested), compared to $8,746 for HSIC. Over the past 12 months, HOLX leads with a +37.1% total return vs ALC's -32.6%. The 3-year compound annual growth rate (CAGR) favors IDXX at 5.6% vs ALC's -4.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -17.4% | -14.6% | -8.2% | +1.9% |
| 1-Year ReturnPast 12 months | -32.6% | +17.6% | +5.9% | +37.1% |
| 3-Year ReturnCumulative with dividends | -12.9% | +17.9% | -11.7% | -8.5% |
| 5-Year ReturnCumulative with dividends | -6.7% | +5.1% | -12.5% | +15.8% |
| 10-Year ReturnCumulative with dividends | +13.0% | +556.2% | +5.3% | +124.3% |
| CAGR (3Y)Annualised 3-year return | -4.5% | +5.6% | -4.0% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than IDXX's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ALC's 65.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 1.36x | 0.72x | 0.45x |
| 52-Week HighHighest price in past year | $97.14 | $769.98 | $89.29 | $76.04 |
| 52-Week LowLowest price in past year | $63.84 | $471.74 | $61.95 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +65.8% | +74.3% | +79.0% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 25.6 | 52.1 | 39.1 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 533K | 1.2M | 10.0M |
Analyst Outlook
ALC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ALC as "Buy", IDXX as "Buy", HSIC as "Hold", HOLX as "Hold". Consensus price targets imply 35.5% upside for ALC (target: $87) vs 3.9% for HOLX (target: $79). ALC is the only dividend payer here at 0.52% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $86.52 | $747.50 | $85.43 | $79.00 |
| # AnalystsCovering analysts | 26 | 22 | 32 | 42 |
| Dividend YieldAnnual dividend ÷ price | +0.5% | — | — | — |
| Dividend StreakConsecutive years of raises | 5 | — | 1 | — |
| Dividend / ShareAnnual DPS | $0.33 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.3% | +2.7% | +10.5% | +4.4% |
IDXX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HSIC leads in 1 (Valuation Metrics). 1 tied.
ALC vs IDXX vs HSIC vs HOLX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ALC or IDXX or HSIC or HOLX a better buy right now?
For growth investors, IDEXX Laboratories, Inc.
(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Alcon Inc. (ALC) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ALC or IDXX or HSIC or HOLX?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IDEXX Laboratories, Inc. wins at 2. 68x versus Henry Schein, Inc. 's 4. 20x.
03Which is the better long-term investment — ALC or IDXX or HSIC or HOLX?
Over the past 5 years, Hologic, Inc.
(HOLX) delivered a total return of +15. 8%, compared to -12. 5% for Henry Schein, Inc. (HSIC). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus HSIC's +5. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ALC or IDXX or HSIC or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 45β versus IDEXX Laboratories, Inc. 's 1. 36β — meaning IDXX is approximately 201% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Alcon Inc. (ALC) carries a lower debt/equity ratio of 24% versus 77% for Henry Schein, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ALC or IDXX or HSIC or HOLX?
By revenue growth (latest reported year), IDEXX Laboratories, Inc.
(IDXX) is pulling ahead at 10. 4% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc. grew EPS 22. 6% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ALC or IDXX or HSIC or HOLX?
IDEXX Laboratories, Inc.
(IDXX) is the more profitable company, earning 24. 6% net margin versus 3. 0% for Henry Schein, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 5. 7% for HSIC. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ALC or IDXX or HSIC or HOLX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, IDEXX Laboratories, Inc. (IDXX) is the more undervalued stock at a PEG of 2. 68x versus Henry Schein, Inc. 's 4. 20x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 2x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 25. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALC: 35. 5% to $86. 52.
08Which pays a better dividend — ALC or IDXX or HSIC or HOLX?
In this comparison, ALC (0.
5% yield) pays a dividend. IDXX, HSIC, HOLX do not pay a meaningful dividend and should not be held primarily for income.
09Is ALC or IDXX or HSIC or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Alcon Inc.
(ALC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 68), 0. 5% yield). Both have compounded well over 10 years (ALC: +11. 4%, IDXX: +542. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ALC and IDXX and HSIC and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
ALC pays a dividend while IDXX, HSIC, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.